Condition: Carcinoma, Pancreatic Ductal · Prognosis · Sponsor: Institut Curie
The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1). Chemotherapy regimen (FOLFIRINOX vs Gem-nabP) will be selected based on transcriptomic signatures applied to the pre-therapeutic liver biopsy of newly diagnosed PDAC patients.
This description comes directly from the study's public registry record.
Cindy NEUZILLET, MD, PhD · +33 (0) 6 82 55 04 92 · cindy.neuzillet@aphp.fr
Marie-Emmanuelle Legrier · drci.promotion@curie.fr
Always discuss trial participation with your own doctor first.
| Hôpital Beaujon | Clichy, France | Recruiting |
| Hôpital HENRI MONDOR | Créteil, France | Recruiting |
| Hôpital Claude Hurriez | Lille, France | Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| CHU Robert Debré | Reims, France | Recruiting |
| Institut Curie | Saint-Cloud, France | Recruiting |
| Hôpital PAUL BROUSSE 12 Avenue Paul Vaillant Couturier | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05475366